113 research outputs found

    Modal analysis of wave propagation in dispersive media

    Full text link
    Surveys on wave propagation in dispersive media have been limited since the pioneering work of Sommerfeld [Ann. Phys. 349, 177 (1914)] by the presence of branches in the integral expression of the wave function. In this article, a method is proposed to eliminate these critical branches and hence to establish a modal expansion of the time-dependent wave function. The different components of the transient waves are physically interpreted as the contributions of distinct sets of modes and characterized accordingly. Then, the modal expansion is used to derive a modified analytical expression of the Sommerfeld precursor improving significantly the description of the amplitude and the oscillating period up to the arrival of the Brillouin precursor. The proposed method and results apply to all waves governed by the Helmholtz equations.Comment: 10 pages, 9 figure

    Broadband suppression of backscattering at optical frequencies using low permittivity dielectric spheres

    Get PDF
    The exact suppression of backscattering from rotationally symmetric objects requires dual symmetric materials where ϵr=μr{\epsilon_r} = {\mu_r}. This prevents their design at many frequency bands, including the optical one, because magnetic materials are not available. Electromagnetically small non-magnetic spheres of large permittivity offer an alternative. They can be tailored to exhibit balanced electric and magnetic dipole polarizabilities, which result in approximate zero backscattering. In this case, the effect is inherently narrowband. Here, we put forward a different alternative that allows broadband functionality: Electromagnetically large spheres made from low permittivity materials. The effect occurs in a parameter regime that approaches the trivial ϵrμr=1{\epsilon_r} \to {\mu_r} =1 case, where approximate duality is met in a weakly wavelength dependence fashion. Despite the low permittivity, the overall scattering response of the spheres is still significant. Radiation patterns from these spheres are shown to be highly directive across an octave spanning band. The effect is analytically and numerically shown using the Mie coefficients.Comment: 6 Figure

    Pharmaceutical Equivalence of Some Conventional Carbamazepine Tablets Marketed in Sudan

    Get PDF
    Background: Carbamazepine (CBZ) is commonly used in the treatment and control of epilepsy, seizures, and neuropathic pain. Due to its limited water solubility, CBZ have slow and variable absorption following oral administration. Effective CBZ plasma levels are achieved through multiple-dose administration of conventional CBZ tablets  which may result in serious side effects because of its narrow therapeutic index and toxicity levels. Objectives: This work aimed at comparing four commercial brands of CBZ tablets (A, B, C and D) manufactured by multinational and national companies including the originator (A) through evaluation of their pharmaceutical equivalence using pharmacoepial and nonpharmacoepial standard tests. Methods: Model-independent approach was used for determination of dissolution efficiency (% D.E) and fit factors.  Difference between brands was demonstrated through analysis of difference (f1) and similarity (f2) data. In addition various quality tests including weight variation, thickness, diameter, hardness, friability and disintegration time were carried out. Results: The study revealed that all brands complied with the USP specifications regarding weight variation, friability disintegration and drug content. The amount of drug released within 45 minutes were found satisfactory and ranged from 83.44% to 94.5%. Although clear differences in release profiles exist, all brands released about 90% of the labeled CBZ within 30 minutes which can satisfy the patient need. Only brand B failed to pass the nonpharmacoepial hardness test. Conclusion: Selected brands of CBZ tablets complied with all required pharmacoepial quality specifications

    PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway

    Get PDF
    Many long noncoding RNAs have been implicated in tumorigenesis and chemoresistance; however, the underlying mechanisms are not well understood. We investigated the role of PRKAR1B-AS2 long noncoding RNA in ovarian cancer (OC) and chemoresistance and identified potential downstream molecular circuitry underlying its action. Analysis of The Cancer Genome Atlas OC dataset, in vitro experiments, proteomic analysis, and a xenograft OC mouse model were implemented. Our findings indicated that overexpression of PRKAR1B-AS2 is negatively correlated with overall survival in OC patients. Furthermore, PRKAR1B-AS2 knockdown-attenuated proliferation, migration, and invasion of OC cells and ameliorated cisplatin and alpelisib resistance in vitro. In proteomic analysis, silencing PRKAR1B-AS2 markedly inhibited protein expression of PI3K-110α and abrogated the phosphorylation of PDK1, AKT, and mTOR, with no significant effect on PTEN. The RNA immunoprecipitation detected a physical interaction between PRKAR1B-AS2 and PI3K-110α. Moreover, PRKAR1B-AS2 knockdown by systemic administration of 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine nanoparticles loaded with PRKAR1B-AS2–specific small interfering RNA enhanced cisplatin sensitivity in a xenograft OC mouse model. In conclusion, PRKAR1B-AS2 promotes tumor growth and confers chemoresistance by modulating the PI3K/AKT/mTOR pathway. Thus, targeting PRKAR1B-AS2 may represent a novel therapeutic approach for the treatment of OC patients

    Antimicrobial resistance among migrants in Europe: a systematic review and meta-analysis

    Get PDF
    BACKGROUND: Rates of antimicrobial resistance (AMR) are rising globally and there is concern that increased migration is contributing to the burden of antibiotic resistance in Europe. However, the effect of migration on the burden of AMR in Europe has not yet been comprehensively examined. Therefore, we did a systematic review and meta-analysis to identify and synthesise data for AMR carriage or infection in migrants to Europe to examine differences in patterns of AMR across migrant groups and in different settings. METHODS: For this systematic review and meta-analysis, we searched MEDLINE, Embase, PubMed, and Scopus with no language restrictions from Jan 1, 2000, to Jan 18, 2017, for primary data from observational studies reporting antibacterial resistance in common bacterial pathogens among migrants to 21 European Union-15 and European Economic Area countries. To be eligible for inclusion, studies had to report data on carriage or infection with laboratory-confirmed antibiotic-resistant organisms in migrant populations. We extracted data from eligible studies and assessed quality using piloted, standardised forms. We did not examine drug resistance in tuberculosis and excluded articles solely reporting on this parameter. We also excluded articles in which migrant status was determined by ethnicity, country of birth of participants' parents, or was not defined, and articles in which data were not disaggregated by migrant status. Outcomes were carriage of or infection with antibiotic-resistant organisms. We used random-effects models to calculate the pooled prevalence of each outcome. The study protocol is registered with PROSPERO, number CRD42016043681. FINDINGS: We identified 2274 articles, of which 23 observational studies reporting on antibiotic resistance in 2319 migrants were included. The pooled prevalence of any AMR carriage or AMR infection in migrants was 25·4% (95% CI 19·1-31·8; I2 =98%), including meticillin-resistant Staphylococcus aureus (7·8%, 4·8-10·7; I2 =92%) and antibiotic-resistant Gram-negative bacteria (27·2%, 17·6-36·8; I2 =94%). The pooled prevalence of any AMR carriage or infection was higher in refugees and asylum seekers (33·0%, 18·3-47·6; I2 =98%) than in other migrant groups (6·6%, 1·8-11·3; I2 =92%). The pooled prevalence of antibiotic-resistant organisms was slightly higher in high-migrant community settings (33·1%, 11·1-55·1; I2 =96%) than in migrants in hospitals (24·3%, 16·1-32·6; I2 =98%). We did not find evidence of high rates of transmission of AMR from migrant to host populations. INTERPRETATION: Migrants are exposed to conditions favouring the emergence of drug resistance during transit and in host countries in Europe. Increased antibiotic resistance among refugees and asylum seekers and in high-migrant community settings (such as refugee camps and detention facilities) highlights the need for improved living conditions, access to health care, and initiatives to facilitate detection of and appropriate high-quality treatment for antibiotic-resistant infections during transit and in host countries. Protocols for the prevention and control of infection and for antibiotic surveillance need to be integrated in all aspects of health care, which should be accessible for all migrant groups, and should target determinants of AMR before, during, and after migration. FUNDING: UK National Institute for Health Research Imperial Biomedical Research Centre, Imperial College Healthcare Charity, the Wellcome Trust, and UK National Institute for Health Research Health Protection Research Unit in Healthcare-associated Infections and Antimictobial Resistance at Imperial College London

    Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

    Get PDF
    Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)
    corecore